Exelixis

This study tests whether a combination of two drugs (cabozantinib and atezolizumab) works better than standard hormone therapy for men with advanced prostate cancer that has stopped responding to initial hormone treatment. About 575 men with metastatic castration-resistant prosta…

This phase 3 trial tests whether adding the targeted drug cabozantinib to a standard immunotherapy combination (nivolumab and ipilimumab) helps people with advanced or metastatic kidney cancer live longer without their disease worsening. About 855 participants with intermediate- …

This study tests whether a new drug combination (XL092 plus atezolizumab) works better than the current standard drug regorafenib for people with advanced colorectal cancer that has spread. About 900 adults whose cancer did not respond to or stopped responding to standard treatme…

This study tests whether the drug cabozantinib can slow the growth of a certain type of advanced thyroid cancer that no longer responds to standard treatments. About 187 adults with this cancer will receive either cabozantinib or a placebo pill. The goal is to see if the drug del…

This study tests whether a combination of two drugs, cabozantinib and atezolizumab, works better than the standard drug sorafenib for people with advanced liver cancer who have not had other cancer treatments. About 837 adults took part. The goal is to see if the new combo helps …

This study tests whether a lower dose (60 mg) of the drug cabozantinib works as well as a higher dose (140 mg) in people with advanced medullary thyroid cancer that has spread. The goal is to see if the lower dose can control the cancer just as long while causing fewer side effec…